Drugs / N-Acetylglucosamine

Trials 3 · a red edge is where a trial was stopped

2016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02511041 Jun 2015 → Jan 2017 National Institute of Allergy and Infectious Diseases (NIAID) Terminated No outcome recorded
Phase 22 trials
Phase 2 NCT07225998 Jun 2026 → Jul 2028 expected Crohn disease Johns Hopkins University Not yet recruiting No outcome recorded
Phase 2 NCT03716115 May 2020 → Apr 2021 protein-energy malnutrition Queen Mary University of London Completed No outcome recorded

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as N-Acetylglucosamine ClinicalTrials.gov intervention name — accepted as the source's own label NCT07225998
2

NCT02511041

NCT03716115

Known as 2- acetylamino)-2- deoxy-D-glucose “N-acetylglucosamine (GlcNAc), 2-acetamino-2-deoxy- \<=-Dglucose, or 2- acetylamino)-2- deoxy-D-glucose, is a monosaccharide derivative of glucose.” NCT02511041
Known as Bio-nag ChEMBL registry synonym — accepted as the source's own label CHEMBL447878
Known as GInNAC “N-Acetyl Glucosamine (GInNAC)” NCT03716115
Known as GlcNAc “N-acetyl glucosamine (GlcNAc) will be given orally or via NG tube for 14 days, gradually increased from a starting dose of 0.5g, to 1g three times daily to avoid osmotic diarrhoea.” NCT03716115
2

“N-acetylglucosamine (GlcNAc), 2-acetamino-2-deoxy- \<=-Dglucose, or 2- acetylamino)-2- deoxy-D-glucose, is a monosaccharide derivative of glucose.” NCT02511041

“N-Acetylglucosamine (GlcNAc)” NCT07225998

Known as Greennag ChEMBL registry synonym — accepted as the source's own label CHEMBL447878
Known as Marine sweet ChEMBL registry synonym — accepted as the source's own label CHEMBL447878
Known as NSC-400525 ChEMBL registry synonym — accepted as the source's own label CHEMBL447878
Known as NSC-524344 ChEMBL registry synonym — accepted as the source's own label CHEMBL447878
Action Restore “GlcNAc administration has been demonstrated to restore the intestinal epithelial charged barrier in Crohn's disease.” NCT03716115
Modality Small molecule “is a monosaccharide derivative of glucose.” NCT02511041
Route Oral “Patients will self-administer oral GlcNAc” NCT02511041